Aloe is a very common plant that belongs to the family of Liliaceae. It is found in tropical regions and it is used for a variety of cosmetics and pharmacological products which are made of the gel found in the large leaves of the plant (Yagi et al, Saudi Pharmaceutical Journal July 2009).
The pharmacological effects of Aloe have been studied in many cases. Aloe has anti-inflammatory action, antibacterial properties, and acts soothingly in arthritis, and finally it presents hypoglycemic action (Newall et al., 1996).
There are clinical studies that could support that aloe has an ability to stabilize the diabetes.
When 2 spoons (0,05gr) of aloe gel was administrated 3 times daily for 12 weeks to Type 2 diabetic patients who did not respond positively to their antidiabetic treatment (metformin, glyburide), the researchers have discovered that fasting glucose of the patients was reduced to 32% from the initial rate together with their triglycerides (Yagi et al, Saudi Pharmaceutical Journal July 2009). Similar were the results of another study in diabetic patients who did not also responded well to their treatment (metformin, glyburide) and to whom aloe gel was administered additionally. Aloe managed to reduce the fasting glucose and the glycosylated hemoglobin of the patients. Also it has to be noted that the total and LDL cholesterol were reduced even if the patients did not receive any other medication (Huseini HF, Planta Med. 2012 Mar).
Some commercial aloe products have been also studied. More specifically, the AC952 and UP780 were given as supplements in doses of 500mg twice a day to pre-diabetic volunteers. The first substance, managed an important reduction at the levels of total and LDL cholesterol, glucose and fructosamine, fasting glucose and HOMA indicator. The results of the above studies reinforce the positive profile of Aloe as an agent which can be used additionally in the improvement of the complications of metabolic syndrome (Devaraj S, Metab Syndr Relat Disord. 2013 Feb).